Friday, February 10, 2023
Boehringer Ingelheim and 3T Biosciences recently announced a strategic collaboration and licencing agreement to address significant unmet patient needs.
Boehringer Ingelheim's two-pronged research strategy combining cancer cell-directed and immune cell-targeting drugs will be combined with 3T Biosciences' best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform, significantly enhancing the pipeline.
The 3T platform intends to overcome this challenge by finding novel common T-cell receptor (TCR) targets of effective immune responses and thoroughly screening TCRs and TCR mimetics for specificity and off-target cross-reactivities.
It aims to discover the most frequent and immunogenic targets in solid tumours by combining high-diversity target libraries with active machine learning. This might result in safer, high-dose medicines that are targeted specifically at the tumour.
Boehringer Ingelheim will contribute patient-derived TCR data as per the conditions of the agreement to support 3T's target discovery activities to identify antigens utilizing its 3T TRACE discovery platform.
In addition, 3T will receive an upfront payment, research and development assistance, and royalties on future Boehringer Ingelheim product sales. 3T will also be eligible for discovery, preclinical, clinical, regulatory, and commercial milestone payments totaling US $268 million.
Boehringer Ingelheim is qualified to collect royalties on any subsequent product sales made by 3T Biosciences, as a result of the arrangement.
